Endocrine Abstracts

Background: Luteinizing hormone (LH) and human chorionic gonadotropin (hCG) act on the same receptor, activating different signal transduction pathways. The role of LH or hCG addition to follicle stimulating hormone (FSH) as well as menopausal gonadotropins (hMG) in controlled ovarian stimulation (COS) is debated.Aim: To compare FSH+LH, or FSH+hCG or hMG vs FSH alone on COS outcomes.Design: A meta-analysis according to PRISMA state...

Ovarian cancer (OC) is the most lethal gynecological cancer. Debulking surgery and platinum-based chemotherapy are the cornerstone of OC management; however, after a partial initial response, tumors invariably relapse. Therapeutic approaches should account for interindividual heterogeneity since OC histiotypes show distinct genetic profile. A2780 cell line has been annotated as high grade serous ovarian cancer (HGSOC); nevertheless, recent research underlined that the genetic ...

Dopamine has been found in both semen and oviductal fluid and dopamine receptors (DRs) have been detected in male genital tract and spermatozoa, suggesting that dopamine system may control important reproductive functions in humans. Dopamine improves sperm motility and viability in animal models, although the underlying molecular mechanisms have not been fully elucidated. The aims of this study were to investigate DRs expression in human spermatozoa and to evaluate the in ...

Introduction: The relationship between SNPs of the FSHR gene and serum FSH has not been completely clarified. Genetic variants of the FSHB gene have been associated to variation in gene transcription and to serum FSH levels in men. An interesting joint effect of both FSHB −211G>T and FSHR 2039 A>G on male reproductive parameters has been recently observed. No data have been published on the effect of the FSHB −211G>T in combination with the FSHR 2039 A&...

Purpose: The present study aimed at investigating the morphology and function of reproductive system in women with hyperprolactinemia (HPRL) receiving chronic treatment with cabergoline (CAB)Methods: Twenty-three women(aged 34.21±10.09 yrs) with HPRL, including 17 with microprolactinoma, 3 with macroprolactinoma and 3 with iatrogenic HPRL, entered the study. All patients were well-controlled with CAB treatment (medium dose 0.46±0.45 mg/week). In po...